Pharmacological management of migraine patients is divided into acute and preventive treatment. This section of the Knowledge Centre features information on current acute and preventive migraine treatment options, as well as information and key research findings on new therapeutic options currently in development.
Choose one of the treatment sub-sections listed below, or scroll down the page, to learn more.
Considering all currently available acute (e.g., NSAIDs, opioids and triptans) and preventive (e.g., tricyclic antidepressants and botulinum toxin type A) treatment options can help you make the right choice for each individual patient and meet therapy goals.
Treating migraine patients in accordance with the recommended treatment care pathways outlined here helps to provide an effective structured management plan including keeping a 'headache diary' to understand triggers and patterns helping to set goals and track progress.
Discover how novel, targeted treatments are presenting exciting new opportunities for migraine control, including small molecule migraine-associated targets such as the 5-HT1F receptor and the calcitonin gene-related peptide (CGRP) and its receptor.
Keeping up-to-date with key research on new migraine therapies can help make informed treatment decisions that suit the individual patient, including: epitinezumab, erenumab, fremanezumab, galcanezumab, ubrogepant (MK-1602) and lasmiditan (COL-144).
Alternatively login via
Back to epgonline.org